Expression of Sema4D and Ki67 in pancreatic carcinoma and its relationship with clinicopathological features
-
摘要:
目的探讨轴突诱导因子4D(Sema4D)和Ki67在胰腺癌中的表达与临床病理特征的关系。方法采用免疫组化(SP)法检测2013年1月-2016年12月邯郸市中心医院收集的40例胰腺癌组织及10例癌旁组织中Sema4D和Ki67蛋白的表达,并分析其与临床病理学特征的关系。2组间计数资料的比较采用χ2检验,相关性分析采用Spearman秩相关法。结果 Sema4D和Ki67在胰腺癌组织中的阳性表达率分别为47.5%(19/40)和45.0%(18/40),高于二者在癌旁组织中的表达,差异均有统计学意义(χ2值分别为10.040、10.000,P值分别为0.020、0.022)。Sema4D和Ki67的异常表达在不同肿瘤分期、淋巴结是否转移的患者中存在显著差异(χ2值分别为6.352、4.912、12.031、6.465,P值分别为0.013、0.028、0.001、0.025)。Sema4D和Ki67的表达呈正相关(r=0.347,P=0.028)。结论在胰腺癌组织中Sema4D和Ki67较其在胰腺癌癌旁组织中的表达明显升高...
-
关键词:
- 胰腺肿瘤 /
- Ki-67抗原 /
- 信号素类 /
- 病理状态,体征和症状
Abstract:Objective To investigate the expression of Sema4 D and Ki67 in pancreatic carcinoma and its relationship with clinicopathological features. Methods The expression of Sema4 D and Ki67 in 40 pancreatic carcinoma tissues and 10 adjacent tissues was measured by immunohistochemistry, and its relationship with the clinicopathological features of pancreatic carcinoma was analyzed. Comparison of categorical data between two groups was made by chi-square test. Spearman's rank correlation analysis was used to identify the correlation between these variables. Results Sema4 D and Ki67 were detected in 19 ( 47. 5% ) and 18 ( 45. 0% ) , respectively, of the 40 pancreatic carcinoma tissues, with significantly higher positive rates than the adjacent tissues ( χ2= 10. 040 and 10. 000, P = 0. 020 and 0. 022) . The abnormal expression of Sema4 D and Ki67 differed significantly between patients with different tumor stages and between patients with and without lymph node metastasis ( χ2= 6. 352, 4. 912, 12. 031, and 6. 465, P = 0. 013, 0. 028, 0. 001, and 0. 025) . Sema4 D expression was positively correlated with Ki67 expression ( r = 0. 347, P = 0. 028) . Conclusion The expression of Sema4 D and Ki67 is elevated in pancreatic carcinoma compared with the adjacent tissue. Their expression is positively correlated with each other and is associated with tumor staging and lymph node metastasis.
-
[1]YOUNIS RH, HAN KL, WEBB T.Semaphorin 4D produced by human head and neck squamous cell carcinoma induces myeloidderived suppressor cells expansion fromperipheral blood monocytes[J].J Immunother Cancer, 2015, 3 (Suppl 2) :280-281. [2]LAIRD A, O'MAHONY FC, NANDA J, et al.Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome[J].PLo S One, 2013, 8 (4) :e60483. [3]WANG YC, QI WQ, ZHAO P.Research advances in insulin-like growth factor-1 receptor in pancreatic cancer[J].J Clin Hepatol, 2017, 33 (4) :790-794. (in Chinese) 王悦超, 亓文骞, 赵平.胰岛素样生长因子1受体在胰腺癌治疗中的机制及进展[J].临床肝胆病杂志, 2017, 33 (4) :790-794. [4]CHEN W, ZHENG R, BAADE PD, et al.Cancer statistics in China, 2015[J].CA Cancer J Clin, 2016, 66 (2) :115-132. [5]GOU SM, WU HS.Developmental history of the extent of lymph node dissection in pancreatic cancer surgery[J].J Clin Hepatol, 2017, 33 (1) :57-60. (in Chinese) 勾善淼, 吴河水.胰腺癌根治术淋巴结清扫范围的发展历程[J].临床肝胆病杂志, 2017, 33 (1) :57-60. [6]YOUNIS RH, HAN KL, WEBB TJ.Human head and neck squamous cell carcinoma-associated Semaphorin 4D induces expansion of myeloid-derived suppressor cells[J].J Immunol, 2016, 196 (3) :1419-1429. [7]CH'NG ES, KUMANOGOH A.Roles of Sema4D and Plexin-B1 in tumor progression[J].Mol Cancer, 2010, 21 (9) :251. [8]KATO S, KUBOTA K, SHIMAMURA T, et al.Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexin B1, in pancreatic cancer[J].Cancer Sci, 2011, 102 (11) :2029-2037. [9]BASILE JR, HOLMBECK K, BUGGE TH, et al.MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D[J].J Biol Chem, 2007, 282 (9) :6899-6905. [10]SOONG J, CHEN Y, SHUSTEF EM, et al.Sema4D, the ligand for Plexin B1, suppresses c-Met activation and migration and promotes melanocyte survival and growth[J].J Invest Dermatol, 2012, 132 (4) :1230-1238. [11]TURKEL KUCUKMETIN N, CICEK B, SARUC M, et al.Ki67 as a prognostic factor for long-term outcome following surgery in gastrointestinal stromal tumors[J].Eur J Gastroenterol Hepatol, 2015, 27 (11) :1276-1280. [12]DRAGOMIR LP, SIMIONESCU C, MARGARITESCU C, et al.P53, P16 and Ki67 immunoexpression in oral squamous carcinomas[J].Rom J Morphol Embryol, 2012, 53 (1) :89-93. [13]ROSSI L, LAAS E, MALLON P, et al.Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma[J].Br J Cancer, 2015, 113 (7) :996-1002. [14]BEUSCHLEIN F, WEIGEL J, SAEGER W, et al.Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection[J].J Clin Endocrinol Metab, 2015, 100 (3) :841. [15]LIU M, LAWSON G, DELOS M, et al.Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis:comparison with clinical and radiologic examinations[J].Head Neck, 2003, 25 (4) :280-288. [16]YUN F, JIA YF, HAN Z, et al.Expression of HIF-2αin non-small cell lung cancer tissue and its relationship with MRD, Ki67, and GST-π[J].J Jilin Univ:Med Edit, 2016, 42 (5) :954-957. (in Chinese) 云芬, 贾永峰, 韩昭, 等.HIF-2d在非小细胞肺癌组织中的表达及其与微血管密度、Ki67和GST-π的关系[J].吉林大学学报:医学版, 2016, 42 (5) :954-957. [17]MU K, WU ZZ, NIU HF, et al.Clinicopathologic characteristics and prognosis of medullary breast carcinoma[J].Chin J Gen Surg, 2017, 32 (3) :211-214. (in Chinese) 穆坤, 吴梓政, 牛海飞, 等.乳腺髓样癌临床病理特征及预后分析[J].中华普通外科杂志, 2017, 32 (3) :211-214. [18]GUO JP, KE QG, YUAN ZN.Correlation analysis between Ki-67and p53 expression in breast cancer tissues and preoperative neoadjuvant chemotherapy[J].Clin J Curr Adv Gen Surg, 2017, 20 (2) :90-92. (in Chinese) 郭金培, 柯其广, 原志男.乳腺癌术前新辅助化疗对p53和Ki-67表达的影响[J].中国现代普通外科进展, 2017, 20 (2) :90-92.
计量
- 文章访问数: 1926
- HTML全文浏览量: 12
- PDF下载量: 423
- 被引次数: 0